Apellis

Apellis Pharmaceuticals, Inc. has a twelve month low of $19.83 and a twelve month high of $94.75.

Hudson Bay Capital Management LP purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $476,000.

Over 1 million people in the US and 5 million worldwide are affected by GA, providing a significant market opportunity for Apellis.

Vanguard Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 8.2% in the 1st quarter.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Oppenheimer & Co. Inc.

Apellis Pharmaceuticals () last posted its earnings results on Tuesday, November 5th.

Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -4.45 earnings per share for the current year.

Eventide Asset Management LLC purchased a new position in Apellis Pharmaceuticals in the fourth quarter valued at $12,558,000.

Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Apellis Pharmaceuticals by 29.3% in the third quarter.

First Horizon Advisors Inc. increased its position in shares of Apellis Pharmaceuticals by 69.0% in the third quarter.

Morgan Stanley began coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st.

Research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.14 EPS for the current fiscal year.

Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th.

Apellis Pharmaceuticals (APLS, 1.83% weight*) climbed nearly 18% last week after announcing positive Phase 2 data for its immunotherapy inhibitor to treat a rare kidney disease.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th.

Zacks Investment Research raised Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th.

Finally, Bank of America Corp DE boosted its holdings in shares of Apellis Pharmaceuticals by 146.0% during the fourth quarter.

Finally, BlackRock Inc. increased its position in Apellis Pharmaceuticals by 1.9% during the third quarter.

SG Americas Securities LLC acquired a new position in shares of Apellis Pharmaceuticals in the 1st quarter valued at approximately $112,000.

SG Americas Securities LLC acquired a new stake in Apellis Pharmaceuticals in the 3rd quarter valued at about $1,585,000.